Condensed Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:
Biocatalyst products	$ 2,985	$ 9,137
Biocatalyst research and development	2,146	1,300
Revenue sharing arrangement	1,943	1,044
Total revenues	7,074	11,481
Costs and operating expenses:
Cost of biocatalyst product revenues	2,524	5,665
Research and development	4,834	7,322
Selling, general and administrative	6,112	8,124
Total costs and operating expenses	13,470	21,111
Loss from operations	(6,396)	(9,630)
Interest income	9	27
Other expenses	(118)	(85)
Loss before income taxes	(6,505)	(9,688)
Benefit from income taxes	(130)	(65)
Net loss	$ (6,375)	$ (9,623)
Net loss per share, basic and diluted (dollars per share)	$ (0.17)	$ (0.25)
Weighted average common shares used in computing net loss per share, basic and diluted (shares)	38,506	37,842